STAT3 and mature T-cell and NK-cell non-Hodgkin lymphoma: To understand the association of JAK-STAT signaling pathway activity with clinical determinants, we combined pY-STAT3, pMAPK, and pAKT proportion defined by IHC with information on PTCL disease histology, stage, peripheral blood lactate dehydrogenase (LD) level at diagnosis, survival status, STAT3 and RHOA mutation status (Figure 6).